Webcasting

Browse by:
Sort by:
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 sessions: 1 to 10 of 27
expand session
Opening Session
Dan Barouch
Conference Chair, Boston, MA United States of America
Amit Dixit
Boston, MA United States of America
Galit Alter
Conference Chair, Boston, MA United States of America
Bill Snow
Global HIV Vaccine Enterprise, New York, NY United States of America
A Memorial Tribute to Dr. Norman Letvin
Gary Nabel and Bart Haynes
Vaccine Research Center and Duke Human Vaccine Institute, USA
Integrating AIDS Prevention and Care in Haiti and Rwanda: A Clinician's View
Paul Farmer
Harvard Medical School, Boston, MA United States of America
Trevor Mundel
Bill & Melinda Gates Foundation, Seattle, WA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 on September 9, 2012 4:30 PM-6:30 PM
expand session
Plenary Session 01: HIV Vaccines in the Broader HIV Prevention Landscape
An HIV Vaccine in the Context of a Combination Non-Vaccine Prevention Program
Anthony Fauci
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Welcome by Governor Deval Patrick
Governor Deval L. Patrick
Boston, MA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
The current state of microbicides as prevention
Salim Abdool Karim
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
 
Slides + audio
 
 
slides video audio and slides mp3
Oral PrEP for HIV Prevention: Next Steps
Jared Baeten
University of Washington, Seattle, WA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
ART for Prevention of HIV: Glimmers of Success
Myron Cohen
University of NC at Chapel Hill, Chapel Hill, NC United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 Plenary on September 10, 2012 8:30 AM-10:30 AM
expand session
Oral Abstract 01: Animal Models
Significant Protection from Infection and AIDS Progression After Gastrointestinal and Oral Vaccinations, Respectively, with a SIV DNA/rMVA Vaccine
Anna Aldovini
Children's Hospital Boston, Harvard Medical School, Pediatrics, Boston, MA United States of America
 
All slides withheld
 
 
audio and slides mp3
Antibodies to the Envelope Protein Protect Macaques from SIVmac251 Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial
Genoveffa Franchini
NCI/NIH, Bethesda, MD United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Immune Control of an SIV Challenge by a Heterolgous and Direct Mucosal Vaccination Regimen in Rhesus Monkeys
Linqi Zhang
Comprehensive AIDS Research Center, Tsinghua University, Beijing, China
 
Slides + audio
 
 
slides video audio and slides mp3
A Recombinant Attenuated Mycobacterium Tuberculosis-SIV Combination Vaccine Is Safe and Immunogenic in Immunocompromised, SIV-Infected Infant Macaques
Kristina Abel
UNC Chapel Hill, Microbiology and Immunology, and CFAR, Chapel Hill, NC United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
MAb PGT121 Protects Against Mucosal SHIV Challenge in Macaques at Concentrations Corresponding to Its Highly Potent In Vitro Neutralization Capacity
Brian Moldt
The Scripps Research Institute, La Jolla, CA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Epitope Specificity Appears to Be an Important Determinant of In Vivo Killing Ability of Simian Immunodeficiency Virus (SIV)-Specific CD8+ T Cells
Lu-Ann Pozzi
Harvard Medical School, Immunology, Southborough, MA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 Oral Abstract on September 10, 2012 11:00 AM-12:30 PM
expand session
Oral Abstract 02: Vaccine Concepts - Protein Immunogens
Identification of a Clade A HIV Envelope Immunogen from Protocol G That Elicits Neutralizing Antibodies to Tier 2 Viruses
Simon Hoffenberg
International AIDS Vaccine Initiative, Brooklyn, NY United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Prime-Boost Regimen Potency and Efficacy with Alphavirus Replicons (SIV Antigen) in Non-human Primates Challenged with Low-Dose Intra-rectal SIVsmE660
Kaustuv Banerjee
Novartis Vaccines and Diagnostics, Cambridge, MA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Minimally Invasive and Surface Electroporation Delivery of DNA Vaccines for the Induction of Robust Humoral Immune Responses Against HIV Antigens
Niranjan Y. Sardesai
Inovio Pharmaceuticals, Blue Bell, PA United States of America
 
Slides + audio
 
 
audio and slides mp3
Design of Lipid Nanoparticle Delivery Agents for Multivalent Display of Recombinant Env Trimers in HIV Vaccination
Sharmila Pejawar-Gaddy
Massachusetts Institute of Technology, Boston, MA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Eliciting Neutralizing Antibodies with gp120 Outer Domain
Yali Qin
Iowa State University, Biomedical Sciences, Ames, IA United States of America
 
Slides + audio
 
 
audio and slides mp3
Oral immunization with a recombinant Lactococcus lactis expressing HIV-1 Gag on the tip of the pilus induces strong mucosal immune responses
Venkateswarlu Chamcha
Emory University, Department of Microbiology and Immunology, Yerkes National Primate Res, Atlanta, GA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 Oral Abstract on September 10, 2012 11:00 AM-12:30 PM
expand session
Oral Abstract 03: Innate Immunity
SIV?nef Vaccination Mobilizes Systemic and Mucosal Natural Killer Cells in Mamu A*01+ Macaques
R. Keith Reeves
NEPRC, Harvard Medical School, Southborough, MA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
RV144-like Trial in Macaques Using ALVAC-SIV & gp120, Induces Innate Immunity and Increases the Frequency of NK22 & NKG2A+ Cells in Mucosal Tissues
Namal P.M. Liyanage
Animal Models & Retroviral Vaccines Section , National Cancer Institute, NIH, Bethesda, MD United States of America
 
Slides + audio
 
 
audio and slides mp3
Adenovirus Vectors from Various Serotypes Induce Distinct Cytokine Profiles
Jeffrey E. Teigler
Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Infiltration of Dendritic Cells and Antigen Uptake in the Muscle After Injection of HIV-1 Env gp120 in Adjuvant
Karin Loré
Karolinska Institutet, Dept of Medicine, Stockholm, Sweden
 
Slides + audio
 
 
slides video audio and slides mp3
Early Pro-inflammatory Host Response to Recombinant HSV-SIV Vaccination in Sooty Mangabeys
Namita Rout
NEPRC-HMS, Immunology, Southborough, MA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transcriptional programs
Erica Andersen-Nissen
Fred Hutchinson Cancer Research Center, VIDD, Seattle, WA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 Oral Abstract on September 10, 2012 11:00 AM-12:30 PM
expand session
Monday Press Conference
Nelson Michael, Chair
US Military HIV Research Program, Bethesda, MD United States of America
Dan Barouch
Harvard Medical, Boston, MA United States of America
Anthony Fauci
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD United States of America
Morgane Rolland
MHRP, HJF, Bethesda, MD United States of America
Salim Abdool Karim
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
Jared Baeten
University of Washington, Seattle, WA United States of America
Mike Cohen
University of NC at Chapel Hill, Chapel Hill, NC United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 Press Conference on September 10, 2012 12:30 PM-1:30 PM
expand session
Oral Abstract 04: Mucosal Immunity
Immune Complexes Can Dampen Inflammatory Signaling at the Mucosal Surface During Protective SIV Vaccination
Anthony J. Smith
University of Minnesota , Minneapolis, MN United States of America
 
Slides + audio
 
 
audio and slides mp3
Vaccine-Elicited Systemic and Mucosal Humoral Responses of Lactating Rhesus Monkeys Vaccinated with the Transmitted/Founder HIV Envelope 1086C
Sallie R. Permar
Duke University Medical Center, Pediatrics, Durham, NC United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Expanded Memory CD4+ T Cells in the Fetal and the Infant Gut; a Mucosal Route for Mother-to-Child-Transmission of HIV-1
Madeleine J. Bunders
Academic Medical Centre, Department of Pediatric Hematology, Immunology and Infectious Diseases, Amsterdam, Netherlands
 
Slides + audio
 
 
slides video audio and slides mp3
Cell Free HIV-1 Virus Can Infect Inner and Outer Foreskin Polarized Explants
Maria P. Lemos
Fred Hutchinson Cancer Research Center, Vaccine and Infectious Diseases Division, Seattle, WA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Inflammation in the Male Genital Tract: Implications for HIV Acquisition and Transmission
Abraham J. Olivier
IIDMM, Division of Medical Virology, University of Cape Town, Clinical Laboratory Sciences, Cape Town, South Africa
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 Oral Abstract on September 10, 2012 1:30 PM-2:45 PM
expand session
Oral Abstract 05: Social/Ethical Issues
An Assessment of Good Participatory Practice Guidelines at HIV Prevention Research Clinical Centers in Eastern and Southern Africa
Prince Bahati
International AIDS Vaccine Initiative, East Africa Regional Office, Nairobi, Kenya
 
Slides + audio
 
 
slides video audio and slides mp3
New Tools to Measure Community and Stakeholder Engagement and Its Impact on Outcomes of Clinical Research
Stacey Hannah
AVAC, New York, NY, United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Social and Ethical Considerations in Engaging American Indian and Alaska Native Communities in HIV Clinical Research
Jessica Velcoff
Fred Hutchinson Cancer Research Center, Legacy Project, Seattle, WA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Knowledge/attitude/practices of HPV & cervical cancer, willingness to participate in vaccine trial in preparation for HIV & HPV vaccine trials in Mali
Danielle Poole
Brown University, Providence, RI United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Referral and Access to Care of HIV Prevalent Cases; Experience from the Early Capture HIV Cohort Study in Kampala
Lillian N. Mutengu
Makerere University Walter Reed Project, Community Outreach , Kampala, Uganda
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 Oral Abstract on September 10, 2012 1:30 PM-2:45 PM
expand session
Oral Abstract 06: V1/V2 Antibody Responses
A Short Segment in the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Neutralization Resistance to PG9-Like Antibodies
Nicole A. Doria-Rose
National Institutes of Health, Bethesda, MD United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Characterization of V1V2-Specific Antibodies Present in Broadly Neutralizing Plasma Isolated from HIV-1 Infected Individuals
Abe Pinter
UMDNJ, Newark, NJ, United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Design of an HIV Env Antigen That Binds with High Affinity to Antibodies Against Linear, Conformational and Broadly Neutralizing Epitopes Within V1/V2
Larry (Huaxin) Liao
Duke University Medical Center, Duke Human Vaccine Institute, Durham, NC United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Evidence for Env-V2 Sieve Effect in Breakthrough SIVMAC251 Infections in Rhesus Monkeys Vaccinated with Ad26/MVA and MVA/Ad26 Constructs
Morgane Rolland
MHRP, HJF, Bethesda, MD United States of America
 
Permission not
granted for presentation
 
 
Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120
Anthony P. West, Jr.
California Institute of Technology, Division of Biology, Pasadena, CA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 Oral Abstract on September 10, 2012 1:30 PM-2:45 PM
expand session
Symposia 01: Exploiting the Innate Immune Response
Development of Dendritic Cell-based Prophylactic and Therapeutic HIV Vaccine
Yves Levy
CHU Henri Mondor, Creteil, France
 
Slides + audio
 
 
slides video audio and slides mp3
Adjuvants Influence the Magnitude, Quality and Durability of HIV Env Specific Humoral Immunity in Non-human Primates
Robert Seder
Vaccine Research Center, National Institutes of Health, Bethesda, MD United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Systems Analysis of HIV Vaccine Triggered Innate Immune Responses
Daniel Zak
Seattle BioMed, Seattle, WA United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
Profiling Humoral Immunity: Determining Antibody Innate Immune Recruiting Capacity
Margaret Ackerman
Thayer School of Engineering, Hanover, NH United States of America
 
Slides + audio
 
 
audio and slides mp3
Natural Killer (NK) Cell Responses at Female Genital Mucosa to SIV Vaginal Challenge
Liang Shang
University of Minnesota, Minneapolis, MN United States of America
 
Slides + audio
 
 
slides video audio and slides mp3
from AIDS Vaccine 2012 Symposium on September 10, 2012 4:00 PM-6:00 PM
<< first | < prev page: of 3 records per page: next > | last >>
pages: 1 2 3 sessions: 1 to 10 of 27